Each mL contains Amikacin (as sulfate) 125 mg.
Each mL contains Amikacin (as sulfate) 250 mg.
Amikacin is a semi-synthetic aminoglycosides antibiotic derived from Kanamycin. It is effective to infections caused by strains resistant to aminoglycosides.
Pharmacology: Pharmacokinetics: Pharmacokinetics studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (20% of the body weight). By the ultra infiltration technique, reports of serum protein binding range from 0 to 11%. The mean serum clearance rate is about 100 mL/min and the renal clearance rate is 94 mL/min in subjects with normal renal function.
For short term treatment of serious infections due to susceptible organisms.
Used intramuscularly and intravenously. 15 mg/kg/day divided into 2-3 equal doses. The usual duration of treatment is 7 to 10 days.
A history of hypersensitivity to amikacin is contraindicated for its use. A history of hypersensitivity of serious toxic reactions to aminoglycosides may contraindicate the use of any other aminoglycosides because of known cross-sensitive of patients to drug in this class.
For patients treated with parenterals, aminoglycosides should be under close clinical observation because of the potential ototoxicity and nephrotoxicity associated with their use. Neurotoxicity, manifested as vestibular and permanent bilateral auditory ototoxicity can occur in patients with pre-existing renal damage and in patients with normal renal function treated at higher doses and for those longer than recommended. Aminoglycosides are potentially nephrotoxic. The risk of nephrotoxicity is greater in patients with impaired renal function and in those who receive higher doses or prolonged therapy.
Amikacin is potentially nephrotoxic, ototoxic, and neurotoxic. Renal function and auditory acuity should be checked during therapy.
Store at temperature not exceeding 30°C.
J01GB06 - amikacin ; Belongs to the class of other aminoglycosides. Used in the systemic treatment of infections.
Soln for inj (vial) 125 mg/mL x 2 mL x 25's. 250 mg/mL x 2 mL x 25's.